Aquilon Pharma secures €6 million in refinancing to support the commercial launch of its nasal product line

This refinancing is based on four complementary and interdependent pillars:

1. The signing of a major commercial agreement with the German company Ursatec, marking a new milestone in the development of our nasal line.
2. The confirmed support of public investors, notably Noshaq and O.B.I./Move Invest, who reaffirm their confidence in Aquilon Pharma’s growth potential.
3. The confirmation of the commitment of our long-standing investors, who continue to actively support our long-term strategy.
4. The renewed support of our banking partners, demonstrating the strength of the project and the credibility of our vision.

Thanks to this fundraising, the launch of the first medical device developed in partnership with Ursatec is fully confirmed for the end of 2025, in line with the established schedule.

Aquilon Pharma would like to thank all its partners for their trust and commitment to this new phase of development.